- Home
- CRBP vs JELD Comparison
CRBP vs JELD Comparison
Compare CRBP & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBP | JELD |
|---|---|---|
| Founded | 2009 | 1960 |
| Country | United States | United States |
| Employees | N/A | 13900 |
| Industry | Biotechnology: Pharmaceutical Preparations | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 168.8M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CRBP | JELD |
|---|---|---|
| Price | $8.38 | $2.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 6 |
| Target Price | ★ $46.17 | $3.43 |
| AVG Volume (30 Days) | 145.8K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.31 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,822,272.00 | ★ $3,211,181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $220.00 | $2.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $1.70 |
| 52 Week High | $20.56 | $6.98 |
Technical Indicators
Market Signals| Indicator | CRBP | JELD |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 37.51 |
| Support Level | $8.39 | $1.70 |
| Resistance Level | $8.43 | $3.12 |
| Average True Range (ATR) | 0.48 | 0.24 |
| MACD | 0.13 | -0.05 |
| Stochastic Oscillator | 79.61 | 15.89 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.